Gyre Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Gyre Therapeutics, Inc. (GYRE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.83M, a 63.66% increase year-over-year.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.83M, a 243.26% increase year-over-year.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.15M, a 383.97% increase year-over-year.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.12M, a 6900.00% increase year-over-year.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.16M, a 761.25% increase from fiscal 2024.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $831.00K, a 88.59% decline from fiscal 2023.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.28M, a 45.53% decline from fiscal 2022.
- Gyre Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $13.37M, a 292.54% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.83M 10-Q · filed 2026-08-07 | $4.66M derived: sum of 2 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $2.83M 10-Q · filed 2026-08-07 | $2.58M 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | $7.16M 10-K · filed 2026-03-13 | |||||
| 2025-09-30 | $1.15M 10-Q · filed 2025-11-07 | $2.27M derived: sum of 2 quarters · filed 2026-08-07 | $3.09M derived: sum of 3 quarters · filed 2026-08-07 | |||
| 2025-06-30 | $1.12M 10-Q · filed 2026-08-07 | $906.00K 10-Q · filed 2025-08-11 | $1.94M derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $823.00K 10-Q · filed 2026-08-07 | $507.00K 10-Q · filed 2025-05-09 | ||||
| 2024-12-31 | $831.00K 10-K · filed 2026-03-13 | |||||
| 2024-09-30 | $237.00K 10-Q · filed 2025-11-07 | $253.00K derived: sum of 2 quarters · filed 2025-11-07 | $264.00K derived: sum of 3 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $16.00K 10-Q · filed 2025-11-07 | $27.00K derived: sum of 2 quarters · filed 2025-11-07 | ||||
| 2024-03-31 | $11.00K 10-Q · filed 2025-11-07 | |||||
| 2023-12-31 | $7.28M 10-K · filed 2025-03-17 | |||||
| 2023-09-30 | $98.00K 10-Q · filed 2023-10-26 | $187.00K derived: sum of 2 quarters · filed 2023-10-26 | $397.00K derived: sum of 3 quarters · filed 2023-10-26 | |||
| 2023-06-30 | $89.00K 10-Q · filed 2023-10-26 | $299.00K derived: sum of 2 quarters · filed 2023-10-26 | ||||
| 2023-03-31 | $210.00K 10-Q · filed 2023-10-26 | |||||
| 2022-12-31 | $13.37M 10-K · filed 2024-03-27 | $1.34M 10-K · filed 2023-03-30 | ||||
| 2022-09-30 | $224.00K 10-Q · filed 2023-10-26 | $570.00K derived: sum of 2 quarters · filed 2023-10-26 | $1.08M derived: sum of 3 quarters · filed 2023-10-26 | |||
| 2022-06-30 | $346.00K 10-Q · filed 2023-10-26 | $861.00K derived: sum of 2 quarters · filed 2023-10-26 | ||||
| 2022-03-31 | $515.00K 10-Q · filed 2023-10-26 | |||||
| 2021-12-31 | $3.40M 10-K · filed 2023-03-30 | |||||
| 2021-09-30 | $713.00K 10-Q · filed 2022-11-14 | $1.70M derived: sum of 2 quarters · filed 2022-11-14 | $2.72M derived: sum of 3 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $983.00K 10-Q · filed 2022-11-14 | $2.01M derived: sum of 2 quarters · filed 2022-11-14 | ||||
| 2021-03-31 | $1.03M 10-Q · filed 2022-11-14 | |||||
| 2020-12-31 | $3.63M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $1.07M 10-Q · filed 2021-11-12 | $1.90M derived: sum of 2 quarters · filed 2021-11-12 | $2.71M derived: sum of 3 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $834.00K 10-Q · filed 2021-11-12 | $1.64M derived: sum of 2 quarters · filed 2021-11-12 | ||||
| 2020-03-31 | $805.00K 10-Q · filed 2021-11-12 | |||||
| 2019-12-31 | $3.20M 10-K · filed 2021-03-04 | |||||
| 2019-09-30 | $801.00K 10-Q · filed 2020-11-05 | $1.70M derived: sum of 2 quarters · filed 2020-11-05 | $2.53M derived: sum of 3 quarters · filed 2020-11-05 | $3.27M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $903.00K 10-Q · filed 2020-11-05 | $1.73M derived: sum of 2 quarters · filed 2020-11-05 | $2.47M derived: sum of 3 quarters · filed 2020-11-05 | $3.18M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $829.00K 10-Q · filed 2020-11-05 | $1.57M derived: sum of 2 quarters · filed 2020-11-05 | $2.28M derived: sum of 3 quarters · filed 2020-11-05 | $2.83M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2018-12-31 | $740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $1.45M derived: sum of 2 quarters · filed 2020-02-20 | $2.00M derived: sum of 3 quarters · filed 2020-02-20 | $2.61M 10-K · filed 2020-02-20 | ||
| 2018-09-30 | $710.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.26M derived: sum of 2 quarters · filed 2019-11-07 | $1.87M 10-Q · filed 2018-11-01 | $2.17M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $550.00K 10-Q · filed 2019-11-07 | $1.16M 10-Q · filed 2018-08-02 | $1.46M derived: sum of 3 quarters · filed 2019-11-07 | $1.79M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-03-31 | $606.00K 10-Q · filed 2019-11-07 | $913.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.24M derived: sum of 3 quarters · filed 2019-11-07 | $1.35M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2017-12-31 | $307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $632.00K derived: sum of 2 quarters · filed 2019-03-08 | $743.00K derived: sum of 3 quarters · filed 2019-03-08 | $863.00K 10-K · filed 2019-03-08 | ||
| 2017-09-30 | $325.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $436.00K derived: sum of 2 quarters · filed 2017-11-02 | $556.00K 10-Q · filed 2017-11-02 | $686.00K derived: sum of 4 quarters · filed 2018-03-19 | ||
| 2017-06-30 | $111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $231.00K 10-Q · filed 2017-08-03 | $361.00K derived: sum of 3 quarters · filed 2018-03-19 | $548.00K derived: sum of 4 quarters · filed 2018-03-19 | ||
| 2017-03-31 | $120.00K 10-Q · filed 2017-05-11 | $250.00K derived: sum of 2 quarters · filed 2018-03-19 | $437.00K derived: sum of 3 quarters · filed 2018-03-19 | $602.00K derived: sum of 4 quarters · filed 2018-03-19 | ||
| 2016-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $317.00K derived: sum of 2 quarters · filed 2018-03-19 | $482.00K derived: sum of 3 quarters · filed 2018-03-19 | $635.00K 10-K · filed 2018-03-19 | ||
| 2016-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $352.00K derived: sum of 2 quarters · filed 2016-11-03 | $505.00K 10-Q · filed 2016-11-03 | $696.00K derived: sum of 4 quarters · filed 2017-03-08 | ||
| 2016-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $318.00K 10-Q · filed 2016-08-04 | $509.00K derived: sum of 3 quarters · filed 2017-03-08 | |||
| 2016-03-31 | $153.00K 10-Q · filed 2016-05-05 | $344.00K derived: sum of 2 quarters · filed 2017-03-08 | ||||
| 2015-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $326.00K 10-K · filed 2017-03-08 | ||||
| 2015-09-30 | $135.00K 10-Q · filed 2015-11-05 | |||||
| 2014-12-31 | $244.00K 10-K · filed 2016-03-09 | $3.47M 10-K · filed 2015-03-16 | ||||
| 2013-12-31 | $298.00K 10-K · filed 2016-03-09 | $5.22M 10-K · filed 2014-03-14 | ||||
| 2012-12-31 | $7.85M 10-K · filed 2015-03-16 | |||||
| 2011-12-31 | $8.51M 10-K · filed 2014-03-14 | |||||
| 2010-12-31 | $4.94M 10-K · filed 2013-03-15 | |||||
| 2009-12-31 | $2.45M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |